James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

5 Top ETFs for Income Investors

Whether you're looking for consistent dividends over time or want to swing big for high yield, these five funds offer something for every income investor.

Automaker Stock Showdown: Ford Vs. GM

If you want to own one American automaker, the best place to start looking at data is in North America ... and Europe ... and China ...

Novartis Flu Vaccine Ban: Who Wins?

Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.

Lesson Learned: The Crocs Fiasco Is Hardly Unusual

Crocs, which not so long ago seemed ready to make a turnaround, just got caught on the wrong side of the "conceptual investing" momentum fence.

The Dow Jones Is Uniquely Screwed

Most of the Dow Jones' biggest weightings are in no position to provide more upside, and even the technicals look ugly -- making for a dour near-term outlook.

Apple Earnings: Expect Something Different

Apple stock traditionally has been trumped up going into earnings, leaving little room for a post-report boost. Things are different this time around.

5 Great Stocks to Buy for Under $5

Stocks with a small sticker price aren't necessarily circling the drain. Here's a look at five underappreciated stocks priced at less than $5 per share.

Monster Beverage-Linked Deaths: Tragic? Yes. Lawsuit-Worthy? No.

The deaths being associated with Monster Beverage's energy drinks are tragic, but the connection and the liability are questionable.

Wall Street’s Third-Quarter Earnings Woes Run Deep and Wide

If it feels like there are a few more red flags than usual waving here in the thick of third-quarter earnings season, you’re not crazy. There are.

3 Ways to Play Housing — Without Betting on Homebuilders

Homebuilders are overcrowded and overbought. You can do better now with companies from these related but overlooked sectors instead.